BusinessBeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in TokyoBy Nasdaq OMXMar 14, 2017, 12:31 PM UTC
BusinessBeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in TokyoBy Nasdaq OMXMar 14, 2017, 12:31 PM UTC
BusinessGenomOncology and med fusion announce the addition of PD-L1 Testing and Interpretation to the LungSEQ® and 50SEQ® Plus FISH TestsBy Nasdaq OMXMar 7, 2017, 2:00 PM UTC
BusinessPeregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXOct 10, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXSep 27, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXSep 21, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXSep 6, 2016, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent DevelopmentsBy Nasdaq OMXMar 9, 2016, 1:00 PM UTC
